查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1468514

特發性肺纖維化治療市場報告（按藥物類別（MAPK 抑制劑、酪胺酸抑制劑、自分泌運動因子抑制劑）、最終用戶（醫院、長期照護機構等）和地區）2024-2032 年

Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-term Care Facilities, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球特發性肺纖維化治療市場規模達38.483億美元。

特發性肺纖維化（IPF）是指直接影響肺部功能的進行性且不可逆的纖維化間質性肺炎。其特徵是肺部形成疤痕組織，從邊緣開始向中心發展，導致呼吸困難和向身體部位輸送氧氣不足。透過胸部影像學檢查、肺活體組織切片、肺功能測試和抗體測試來診斷。兩種最常用的抗纖維化療法包括尼達尼布和吡非尼酮藥物，它們可以改善肺功能並最大限度地降低急性呼吸系統惡化的風險。它們通常與氧氣治療和安寧療護相結合，以提供舒適感並促進患者康復。

纖維化疾病的盛行率不斷上升，以及全球老年人口的不斷增加，是推動市場成長的關鍵因素之一。此外，生活方式的改變和香菸等尼古丁產品消費的增加正在推動市場成長。此外，吸菸被認為是 IPF 發生的最常見原因之一。與此一致的是，大眾對IPF有效管理策略的健康意識不斷增強，也有助於市場的成長。此外，新藥的出現以及 IPF 診斷和治療方法的進步也是其他生長誘導因素。再加上廣泛的研發（R＆D）活動以及醫療保健基礎設施的改進，代表了預計將進一步推動市場的其他一些因素。

本報告回答的關鍵問題：

  • 迄今為止，全球特發性肺纖維化治療市場表現如何，未來幾年又會如何表現？
  • COVID-19對全球特發性肺纖維化治療市場有何影響？
  • 主要區域市場有哪些？
  • 根據藥物類別分類的市場是怎麼樣的？
  • 基於最終用戶的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球特發性肺纖維化治療市場的結構如何？
  • 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球特發性肺纖維化治療市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依藥物類別

  • MAPK抑制劑
    • 市場走向
    • 市場預測
  • 酪胺酸抑制劑
    • 市場走向
    • 市場預測
  • 自分泌運動因子抑制劑
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按最終用戶

  • 醫院
    • 市場走向
    • 市場預測
  • 長期照護設施
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 9 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 10 章：價值鏈分析

第 11 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 12 章：價格分析

第13章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AdAlta Pty Ltd.
    • Angion Biomedica Corp.
    • Boehringer Ingelheim International GmbH (CH Boehringer Sohn AG & Co. KG)
    • Bristol-Myers Squibb Company
    • Cipla Inc.
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • Fibrogen Inc.
    • Galapagos NV
    • Liminal BioSciences Inc.
    • Medicinova Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Vectura Group Plc
Product Code: SR112024A2507

The global idiopathic pulmonary fibrosis treatment market size reached US$ 3,848.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 6,980.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.6% during 2024-2032.

Idiopathic pulmonary fibrosis (IPF) refers to a progressive and irreversible fibrosing interstitial pneumonia that directly impacts the functioning of the lungs. It is characterized by the formation of scar tissue within the lungs that starts at the edges and progresses toward the center, thus causing difficulties in breathing and insufficient delivery of oxygen to the body parts. It is diagnosed through chest imaging studies, lung biopsies, pulmonary function tests and antibody tests. Two of the most commonly used antifibrotic therapy includes nintedanib and pirfenidone-based drugs, which improves lung functioning and minimizes the risks of acute respiratory deterioration. They are often coupled with oxygen therapy and palliative care to provide comfort and improve the recovery of the patient.

The increasing prevalence of fibrotic diseases, along with the rising geriatric population across the globe, is one of the key factors driving the growth of the market. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products, such as cigarettes, is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes is considered as one of the most common causes for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favoring the growth of the market. Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global idiopathic pulmonary fibrosis treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug class and end user.

Breakup by Drug Class:

MAPK Inhibitors

Tyrosine Inhibitors

Autotaxin Inhibitors

Breakup by End User:

Hospitals

Long-term Care Facilities

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc.

Key Questions Answered in This Report:

  • How has the global idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global idiopathic pulmonary fibrosis treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global idiopathic pulmonary fibrosis treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Idiopathic Pulmonary Fibrosis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 MAPK Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Tyrosine Inhibitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Autotaxin Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Long-term Care Facilities
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AdAlta Pty Ltd.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
    • 13.3.2 Angion Biomedica Corp.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Bristol-Myers Squibb Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Cipla Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 SWOT Analysis
    • 13.3.7 Fibrogen Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Galapagos NV
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Liminal BioSciences Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
    • 13.3.10 Medicinova Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Merck & Co. Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Novartis AG
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Vectura Group Plc
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2023
  • Figure 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 7: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: North America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: North America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Canada: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Canada: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: China: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: China: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Australia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Australia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Europe: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Germany: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Germany: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: France: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: France: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Italy: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Italy: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Spain: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Spain: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Russia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Russia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
  • Figure 68: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
  • Figure 69: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market Structure
  • Table 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players